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Abstract 
 
Background and aim. The safety and effectiveness of an HPN program depends on both the expertise 
and the management procedures of the HPN center. We aimed to know the modalities needed to 
provide the home parenteral nutrition (HPN)-program and the types of intravenous supplementation 
(IVS)-admixtures supplied to patients with chronic intestinal failure (CIF) in different countries. 
Methods. In March 2015, 65 centers from 22 countries enrolled 3239 patients (benign disease 90.1%, 
malignant disease 9.9%), recording the patient, CIF and HPN characteristics in a structured database. 
The HPN-provider was categorized as health care system local pharmacy (LP) or home care company 
(HCC). The IVS-admixture was categorized as fluids and electrolytes alone (FE) or parenteral nutrition, 
either commercially premixed (PA) or customized to the individual patient (CA), alone or plus extra FE 
(PAFE or CAFE). 
Results. HPN-provider: HCC 66%, LP 34%; no difference between benign-CIF and malignant-CIF. LP 
was the main modality in 11 Countries; HCC prevailed in 4 European countries, Israel, USA, South 
America and Oceania (p<0.001). IVS-admixture: FE 10%, PA 17%, PAFE 17%, CA 38%, CAFE 18%. 
PA+PAFE use was greater in malignant-CIF and CA+CAFE use was greater in benign-CIF (p<0.001). 
PA+PAFE prevailed in those Countries where LP was the main HPN-provider and CA+CAFE prevailed 
where the main HPN-provider was HCC (p<0.001).  
Conclusions. The HPN provision and the IVS-admixture types differ greatly among countries, among 
HPN centers and between benign-CIF and malignant-CIF. As both HPN provider and IVS-admixture 
types may play a role in the safety and effectiveness of HPN therapy, criteria to homogenize HPN 
programs are needed, to give patients the same opportunity to receive appropriate HPN therapy. 
Keywords: Intestinal failure, home parenteral nutrition, management, intravenous supplementation, 
cancer.
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Introduction 
Home parenteral nutrition (HPN) is the primary and life-saving treatment for patients with 
chronic intestinal failure (CIF) [1]. Intestinal failure (IF) is defined as the “reduction of gut function 
below the minimum necessary for the absorption of macronutrients and/or water and electrolytes, 
such that intravenous supplementation (IVS) is required to maintain health and/or growth” [2]. 
Chronic IF can be due to five pathophysiological mechanisms (short bowel, intestinal fistulas, 
intestinal dysmotility, intestinal mechanical occlusion, or extensive small bowel mucosa disease) 
which can originate from either non-malignant (benign-CIF) or malignant (malignant-CIF) diseases [2]. 
Patients with CIF require IVS for months, years or lifelong [1,2]. They are discharged onto HPN 
programs which aim to provide evidence-based therapy, to prevent HPN-related complications, such 
as central venous catheter (CVC)-related infections and metabolic complications, and to maximize the 
patient/family quality of life (QoL) [3,4]. The European Society for Clinical Nutrition and metabolism 
(ESPEN) guidelines on benign-CIF recommend that at discharge: patients are metabolically stable, able 
physically and emotionally to cope with the HPN therapy, and have an adequate home environment; 
patients should be cared for by a multidisciplinary team with skills and experience in IF and HPN 
management; patient/caregiver training for HPN management should be patient-centered with a 
multidisciplinary approach, together with written guidelines; HPN patients should have access to 
infusion pumps or devices with specified safety features together with ancillary products, safe 
compounding and delivery systems. Thus, the safety and effectiveness of a HPN program depends on 
the expertise and the management modalities of the HPN center. 
It is known that the management and the provision of HPN programs differ greatly among 
countries and among HPN centers. However, only one study, performed in 2010, objectively 
described this feature [5]. Using the ESPEN database for CIF, we have carried out an international 
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cross-sectional survey to know the modalities used to provide the HPN-program and the types of IVS-
admixtures supplied to patients with CIF. 
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Materials and methods 
This international cross-sectional observational study comprises the largest study protocol 
approved by the Home Artificial Nutrition and Chronic Intestinal Failure (HAN&CIF) special interest 
group of ESPEN, which aims to investigate the applicability of the clinical classification of CIF [6]. The 
HPN centers’ recruitment, the patient inclusion criteria, the modalities of data collection and the 
recorded items have been already extensively described [6] and are summarized below. 
Participating centers and patient enrollment criteria 
Sixty-five HPN centers from 22 countries enrolled all adult patients (≥ 18 year old) who were 
on HPN for either benign-CIF or malignant-CIF on March 1st 2015. The term malignant-CIF indicates 
the presence of an active malignant disease at time of enrollment on the study (and thus excludes, for 
example, patients with IF as a result of radiotherapy in whom the malignancy has been cured; these 
patients were surveyed within the benign-CIF group).  
Data collection and schedule 
Data were collected into a structured questionnaire embedded in an Excel (Microsoft Co., 
2013) database, termed “the CIF Action day”, available at the web page of the HAN&CIF group on the 
ESPEN website [7].  
Demographic, clinical, CIF, underlying disease, IVS and HPN program characteristics were 
gathered, and the clinical classification of CIF was calculated for each patient [6]. The HPN-provider 
was categorized as health care system local pharmacy (LP) or home care company (HCC). By HPN-
provider was meant the supplier to the patient of the IVS-admixture, the infusion pump or regulatory 
device and the ancillaries for infusion-line management and CVC medication. The IVS-admixture was 
categorized as: fluids and electrolytes (FE); commercially premixed ready-to-use parenteral nutrition 
admixture (PA); commercially premixed parenteral nutrition admixture plus extra FE (PAFE); 
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parenteral nutrition admixture customized (tailored) to the individual patient requirements (CA); 
parenteral nutrition admixture customized to the individual patient requirements alone or plus extra 
FE (CAFE). 
Ethical statement 
The research was based on anonymized information taken from patient records at the time of 
data collection. The study was conducted with full regard to confidentiality of the individual patient. 
Ethical committee approval was obtained by the individual HPN centers according to local regulations. 
The collected data were used only for the study purpose. The identity of the contributing centers has 
also been anonymized for data analysis and presentation. 
Statistical analysis 
The daily mean volume and energy of IVS were calculated as follows: daily total volume 
(mL/day) or energy (kcal/day) = amount per day of infusion x number of infusions per week / 7; daily 
volume or energy per kg of patient body weight (mL/kgBW/day or kcal/kgBW/day) = amount per day 
of infusion x number of infusions per week) / 7 / kg patient body weight. The patients’ body mass 
index (BMI) was calculated by Quetelet’s formula (weight (kg) / height (m2).      
Data are reported as mean ± standard deviation (SD) and as absolute and relative frequencies. 
The non-parametric Kruskal Wallis test, the Fisher’s exact test and the Chi-square test were applied 
where appropriate.  
The IBM SSPS Statistics package for Windows, version 23.0 (BM Co., Armonk, NY, USA) was 
used for the analyses. Two-tailed p values less than 0.05 were considered as statistically significant. 
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Results 
Participating centers and patient cohorts  
A total of 3239 patients were included, 2919 benign-CIF (90.1%) and 320 malignant-CIF (9.9%) 
(Table 1).  All the HPN centers enrolled benign-CIF patients, while only 45 of them enrolled malignant-
CIF. The malignant-CIF cohort had statistically significant older age, lower BMI, shorter duration of 
HPN, IVS of greater daily volume and energy, and a 10 times greater percentage of patients with IF 
due to mechanical occlusions, (Table 2). In both benign-CIF and malignant-CIF, two-thirds of patients 
were female. 
In the benign-CIF cohort, the underlying diseases were Crohn’s disease 22.4%, mesenteric 
ischemia 17.7%, surgical complications 15.8%, primary chronic intestinal pseudo-obstruction 9.7%, 
radiation enteritis 7.3%, others (<3% each-one) 21.3%, and not reported 5.9%. In the malignant-CIF 
cohort, the type of cancer was not specified 62%, gastrointestinal 28%, extra-abdominal 10%. 
Concurrent enteritis due to radio- or chemo-therapy was described in 5% of cases, and peritoneal 
carcinomatosis was reported in 12%. 
 
 HPN-providers and IVS-admixture types in the total group 
The HPN-provider was not reported in 11 cases and was LP in 1111 (34.4%) and HCC in 2117 
(65.6%) cases. The IVS-admixture type was FE in 312 (9.7%), PA in 556 (17.2%) and PAFE in 541 
(16.8%), CA in 1227 (37.9%) and CAFE in 595 (18.4%) cases. The IVS-admixture types significantly 
differed between the two modalities of HPN provision. When the HPN was provided by a HCC, the 
IVS-admixtures were CA or CAFE in two-thirds of cases, while PA or PAFE accounted for more than 
50% of the IVS-admixtures provided by the LPs (Table 3). 
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HPN-providers and IVS-admixture types by countries 
HCCs provided all HPN in the UK and Israel, were almost exclusive providers (≥80% of patients) 
in the USA, Mexico and South America, and were the main providers (56-63% of cases) in France, 
Italy, Poland and Oceania. LPs provided all the HPN programs in Denmark, two thirds of programs in 
The Netherlands and more than 90% of cases in the other 9 European countries which contributed to 
the survey (Figure 1). 
In those countries, excepting Poland, where most or all the HPN programs were provided by a 
HCC, CA and CAFE represented more than 50% of the IVS-admixtures. Where the LP was the main 
HPN-provider, PA and PAFE prescription prevailed (Figure 2).  
HPN-providers and IVS-admixture types by the nature of the underlying disease 
The percentage split of the two HPN-providers did not differ between benign-CIF and 
malignant-CIF, while CA and CAFE were the IVS-admixture types in almost two-thirds of benign-CIF 
and PA and PAFE were the IVS-admixture types in more than 50% of malignant-CIF (Figure 3). 
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Discussion  
This international survey shows that the modalities of HPN provision and the type of IVS-
admixture supplied significantly differ among countries and between benign-CIF and malignant-CIF. 
Although it is well known that HPN management is not homogeneous among countries or among HPN 
centers within an individual country, this is the first study that gives objective data on this aspect. The 
strengths of the study are the large numbers of participating countries, and the worldwide 
distribution of contributing HPN-centers and enrolled patients. The main limitation of the study is the 
relatively small number of malignant-CIF patients, in comparison with those with benign-CIF (Table 1). 
Actually, the percentage of enrolled patients with malignant-CIF is lower than that expected on the 
basis of previous early and recent surveys on HPN [8-13]. This could be due to the voluntary basis of 
the HPN center participation, that could have attracted primarily those centers mainly caring for 
benign-CIF. Indeed, it may be that in individual countries, most of the patients on HPN for cancer are 
managed by specialists other than those caring for CIF, such as oncologists or internists. Another 
explanation could be that, in previous surveys on HPN prevalence, a percentage of patients with a 
diagnosis of cancer may have not had CIF, being on HPN because of refusal of an otherwise working 
gut, or just because they already had a CVC positioned for chemotherapy. However, as expected, the 
benign-CIF and the malignant-CIF cohorts of the present study consistently differed for all the clinical 
and IVS characteristics, thus supporting the representativeness of the malignant-CIF cohort (Table 2). 
Overall, the prescribed IVS-admixture type and the HPN-providers looked associated. 
Commercially PA or PAFE were more frequently used when the LP was the HPN-provider, while CA or 
CAFE were more frequently used when the HPN-provider was a HCC (Table 3). This would indicate 
that, when required, a HCC makes it easier to supply a tailored IVS-admixture. Indeed, as CIF is a rare 
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condition, not all the LP may have developed the expertise and/or implemented the facilities to 
produce CA in a sufficient quantity to overcome the production costs.  
The data confirm that the HPN provision modalities differ greatly among the individual 
countries, with a range of 0 to 100% of cases for both HCC and LP (Figure 1). The association between 
the HPN provision modality and the IVS-admixture types reported in the total cohort, was observed 
also in the individual countries (Figure 2). The primary aims of an HPN program are prevention of 
HPN-related complications and maximization of the patient/family QoL [3]. The protocol for 
patient/caregiver training and the facilities and ancillaries for IVS management may be very relevant 
to the CVC-related complications, and the availability of a portable infusion pump may significantly 
change the QoL of patients [3]. Differences between means of HPN provision may therefore have 
implications to the safety and efficacy of an HPN program. This suggests that criteria for the 
implementation of HPN provision should be formally devised, in order to homogenize this feature of 
the HPN program and to give patients the same opportunity to receive appropriate HPN therapy 
regardless of where they live. 
The results showed that IVS-admixture types but not the HPN-provider differed between 
benign-CIF and malignant-CIF. The IVS-admixtures tailored to the patient requirements (CA and CAFE) 
were mainly used in benign-CIF, while premixed, ready-to-use, IVS-admixture (PA and PAFE) were 
mainly used in malignant-CIF (Figure 3). This difference may be due to the characteristics of the two 
patient populations, in terms of pathophysiological mechanisms of IF as well as in the aims of the HPN 
program and the expected patient outcome. The clinical scenarios of benign-CIF and malignant-CIF 
are quite different.  In malignant-CIF, the cause of IF was more homogeneous, being represented by 
mechanical obstruction in almost 50% of cases, often due to peritoneal carcinomatosis. In benign-CIF, 
the mechanisms of IF were represented by SBS and fistula in almost 70% of patients. The oral food 
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and beverage intakes and the intestinal fluid and electrolytes losses may greatly differ among patients 
[6]. Patients with benign CIF have a high survival probability, may have good probabilities of intestinal 
rehabilitation and programs aim for social-working-familial rehabilitation and good QoL. Most of the 
patients are independent from a caregiver and do not need any home healthcare assistance [3]. This 
scenario often needs a fine tuning of the HPN program, requiring tailored IVS-admixture in order to 
maximize the prevention of long-term metabolic complications as well as the daily time free of IVS 
infusion. In patients with malignant-CIF, HPN may be required while waiting for or during cancer-
directed treatment, on symptomatic treatment, and/or receiving palliative care [4]. The expected 
duration of HPN is much shorter, either because of a transient need related to cancer treatment plans 
or to short life expectancy of advanced cancer. These patients are often home-bound, dependent on a 
caregiver and require home healthcare assistance. Safety of the line infusion is a priority of any HPN 
program, while the risk of metabolic complications may be lower in the short term. In this scenario, 
premixed ready-use IVS-admixtures may adequately fit with the requirements of the patient with 
malignant-CIF. The lack of differences in HPN-provider between benign-CIF and malignant-CIF was 
probably due to the bias in the enrollment of the HPN centers, that were mostly devoted to benign-
CIF, so that the same HPN provider may have been used for the few patients with malignant-CIF 
enrolled. 
In conclusion, the HPN provision modalities and the IVS-admixture types differ greatly among 
countries and between benign-CIF and malignant-CIF. As both HPN provider and IVS-admixture types 
may play a role in the safety and effectiveness of a HPN program, these data indicate the need to 
devise criteria to homogenize these essential features of HPN, in order to give all patients with CIF the 
same opportunity to receive this life-saving  therapy in the appropriate modality. 
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Table 1. Patients on home parenteral nutrition for chronic intestinal failure (CIF) due to non-
malignant (benign) or malignant disease, enrolled by countries contributing in the survey. 
 Total Benign-CIF Malignant-CIF 
  n. n. (%) n. (%) 
UK 781 738 (94.5) 43 (5.5) 
France 478 441 (92.3) 37 (7.7) 
Italy 362 326 (90.1) 36 (9.9) 
Poland 283 224 (79.2) 59 (20.8) 
Denmark 262 233 (88.9) 29 (11.1) 
The Netherlands 257 229 (89.1) 28 (10.9) 
Spain 43 40 (93.0) 3 (7.0) 
Slovenia 39 31 (79.5) 8 (20.5) 
Sweden 25 24 (96.0) 1 (4.0) 
Hungary 22 20 (90.9) 2 (9.2) 
Belgium 21 21 (100) 0 
Germany 10 1 (10) 9 (90) 
Bulgaria 5 4 (80) 1 (20) 
Croatia 3 3 (100) 0 
Lithuania 3 2 (66.7) 1 (33.3) 
    
USA 429 389 (90.7) 40 (9.3) 
    
Israel 90 71 (78.9) 19 (21.1) 
    
Mexico 4 3 (75) 1 (25) 
Argentina 44 44 (100) 0 
Brasil 7 7 (100) 0 
    
Australia 44 41 (93.2) 3 (6.8) 
New Zealand 27 27 (100) 0 
        
Total 3239 2919 (90.1) 320 (9.9) 
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Table 2. Characteristics of the cohorts of patients with chronic intestinal failure (CIF) enrolled in the 
study: patients without malignant disease (Benign-CIF), n. 2919; patients with a malignant disease 
(Malignant-CIF), n.320. 
 Benign-CIF Malignant-CIF P 
Gender 
 
Males 
Females 
 
 
36.8% 
63.2% 
 
 
39.45 
60.6% 
0.202 
Age, years 54.9±16.0 60.6±13.5 <0.001 
BMI, kg/m2 22.2±4.4 21.5±4.4 0.002 
HPN duration, months 58.1±71.5 17.1±30.9 <0.001 
Pathophysiological mechanism of IF 
 
SBS-J 
SBS-JC 
SBS-JIC 
Fistulas 
Dysmotility 
Mechanical Obstruction 
Mucosal Disease 
 
 
38.6% 
19.9% 
 5.9% 
 7.0% 
17.5% 
 4.4% 
 6.8% 
 
 
28.8% 
 9.7% 
 2.8% 
 3.4% 
 3.4% 
45.9% 
 5.9% 
<0.001 
IVS volume, mL/day 1877.0±1016.6 1967.6±817.8 0.004 
IVS energy, kcal/day 1088.0±649.4 1315.9±560.9 <0.001 
Clinical classification of CIF (IVS, mL/day) 
 
FE1, ≤1000 
FE2, 1001-2000 
FE2, 2001-3000 
FE4, >3000 
 
PN1, ≤1000 
PN2, 1001-2000 
PN3, 2001-3000 
PN4, >3000 
 
 
 
5.8% 
2.2% 
0.5% 
0.3% 
 
15.9% 
40.9% 
23.1% 
11.3% 
 
 
3.1% 
1.3% 
0 
0 
 
10.3% 
47.2% 
29.4% 
8.8% 
<0.001 
BMI, body mass index; HPN, home parenteral nutrition; SBS-J, short bowel syndrome with end jejunostomy; SBS-JC, short 
bowel syndrome with jejuno-colon anastomosis; SBS-JIC, short bowel syndrome with jejuno-ileo anastomosis and total 
colon: IVS, intravenous supplementation; FE, fluid and electrolytes; PN, parenteral nutrition 
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Table 3. Intravenous supplementation (IVS)-admixture type by home parenteral nutrition (HPN)-
provider in patients with chronic intestinal failure (P<0.001) 
 
 
Total 
n. 
FE 
n. (%) 
PA 
n. (%) 
PAFE 
n. (%) 
CA 
n. (%) 
CAFE 
n. (%) 
P 
HCC 2117 224 (10.5) 149 (7.0) 304 (14.3) 906 (42.8) 534 (25.2) <0.001 
LP 1111 88 (7.9) 407 (36.6) 237 (21.3) 318 (28.6) 61 (5.4)  
 
HCC, home care company 
LP, health care system local pharmacy 
FE, fluids and electrolytes 
PA, commercially premixed ready-to-use parenteral nutrition admixture 
PAFE, commercially premixed ready-to-use parenteral nutrition admixture plus extra fluids and 
electrolytes 
CA, parenteral nutrition admixture customized (tailored) to the individual patient requirements 
CAFE, parenteral nutrition admixture customized (tailored) to the individual patient requirements plus 
extra fluids and electrolytes 
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Figure 1. Home parenteral nutrition (HPN)-providers by countries in patients with chronic intestinal failure. LP, health care system local pharmacy. 
HCC, home care company. (P<0.001) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Europe others: Belgium, Bulgaria,Croatia, Germany, Hungary, Lithuania, Slovenia, Spain, Sweden. Oceania: Australia, New Zealand 
S. America: Argentina, Brasil 
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Figure 2. Intravenous supplementation (IVS)-admixture type by countries in patients with chronic intestinal failure. FE, fluids and electrolytes; PA, 
commercially premixed ready-to-use parenteral nutrition admixture; PAFE, commercially premixed ready-to-use parenteral nutrition admixture 
plus extra fluids and electrolytes; CA, parenteral nutrition admixture customized (tailored) to the individual patient requirements; CAFE, 
parenteral nutrition admixture customized (tailored) to the individual patient requirements plus extra fluids and electrolytes (P<0.001) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Europe others: Belgium, Bulgaria,Croatia, Germany, Hungary, Lithuania, Slovenia, Spain, Sweden. Oceania: Australia, New Zealand 
S. Am.: Argentina, Brasil 
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Figure 3. Home parenteral nutrition (HPN)-provider (P=0.083) and intravenous supplementation (IVS)-admixture type (P<0.001) by nature of the 
underlying disease in patients with chronic intestinal failure. 
HPN-provider: LP, health care system local pharmacy. HCC, home care company. 
IVS-admixture:  FE, fluids and electrolytes; PA, commercially premixed ready-to-use parenteral nutrition admixture; PAFE, commercially premixed 
ready-to-use parenteral nutrition admixture plus extra fluids and electrolytes; CA, parenteral nutrition admixture customized (tailored) to the 
individual patient requirements; CAFE, parenteral nutrition admixture customized (tailored) to the individual patient requirements plus extra 
fluids and electrolytes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
